Table 4.
Exploratory metaregression for the association between patient-important outcomes and specification as primary outcome
| Variable | Univariate | Multivariate* | ||
|---|---|---|---|---|
|
|
|
|||
| OR (95% CI) | p value | OR (95% CI) | p value | |
| Industry funding | 1.3 (0.6–2.7) | 0.5 | — | — |
|
| ||||
| Author epi/stats degree | 2.1 (1.1–4.0) | 0.025 | 2.1 (1.1–4.0) | 0.025 |
|
| ||||
| Noninferiority trial | 0.5 (0.2–1.5) | 0.2 | 0.6 (0.2–1.6) | 0.3 |
|
| ||||
| Split-body/crossover trial | 2.1 (0.6–7.0) | 0.2 | 2.0 (0.6–6.4) | 0.3 |
|
| ||||
| Journal impact factor | 1.0 (0.9–1.1) | 0.8 | — | — |
|
| ||||
| Total sample size | 0.99 (0.98–1.1) | 0.2 | 0.99 (0.98–1.1) | 0.6 |
|
| ||||
| Multicentre trial | 0.9 (0.6–1.2) | 0.5 | — | — |
|
| ||||
| Registered trial | 1.0 (0.7–1.4) | 0.9 | — | — |
CI = confidence interval; OR = odds ratio.
*
Variables included in multivariate analysis only if p < 0.25 in univariate analysis.